Streetbeat News

Stock Prices

SWTX

The FDA has approved SpringWorks Therapeutics Inc's Ogsiveo for adult patients with progressing desmoid tumors, marking it as the first drug for this condition. The approval is based on the Phase 3 DeFi trial results, which showed a 71% reduction in the risk of disease progression and a 41% objective response rate compared to placebo. Ogsiveo will be available in the U.S. soon and a European application is expected in the first half of 2024. Analysts project U.S. sales of $3 million in 2023, $79 million in 2024, and peak sales of $544 million in 2032. SpringWorks' shares rose 9.24% in premarket trading.

Portfolio Pulse from Vandana Singh

November 28, 2023 | 11:43 am

ROI

Milton Ault, a 10%+ owner of RiskOn International, reported the purchase of 2,133 shares at an average price of $0.39 per share in a Form 4 filing on Monday.

Portfolio Pulse from Charles Gross

November 28, 2023 | 11:41 am

AIM

BBGI

ICU

ROI

Insiders at four US-listed companies have recently made notable purchases of their own company's stock. SeaStar Medical Holding Corporation (ICU) Director Kenneth Heel Van bought 100,000 shares. Beasley Broadcast Group, Inc. (BBGI) CEO Caroline Beasley acquired 2,712 shares. RiskOn International, Inc. (ROI) 10% owner Milton C. Ault III purchased 2,133 shares. AIM ImmunoTech Inc. (AIM) CEO and President Thomas K Equels bought 33,861 shares. These transactions occurred despite recent financial setbacks for these companies, such as posting wider-than-expected quarterly losses or experiencing significant stock price declines.

Portfolio Pulse from Lisa Levin

November 28, 2023 | 11:39 am

DOGEUSD

Dogecoin (DOGE) has surpassed 5 million holders, with a significant increase in active addresses and confirmed transactions. However, less than 5,000 addresses control over 80% of DOGE's supply. The market capitalization of DOGE has increased by 14% this month, nearing $11 billion. Analyst Tony 'The Bull' suggests a potential rally based on the Parabolic Stop and Reverse (SAR) indicator, which previously preceded a 23,000% rally.

Portfolio Pulse from Mehab Qureshi

November 28, 2023 | 11:38 am

LLY

NVO

Truveta Research's study shows Eli Lilly's Mounjaro (tirzepatide) is more effective for weight loss than Novo Nordisk's Ozempic (semaglutide) in overweight or obese adults. Mounjaro patients lost significantly more weight over various time frames compared to Ozempic patients, with similar rates of gastrointestinal adverse events. LLY stock is slightly down by 0.10%, while NVO stock is down 1.48% in premarket trading.

Portfolio Pulse from Vandana Singh

November 28, 2023 | 11:34 am

CAN

Canaan Inc. (NASDAQ: CAN) reported a significant increase in Q3 earnings per share (EPS) at $0.47, up from $0.04 year-over-year (YoY), marking a 1075% increase. The company's sales for the quarter were $33.32 million, surpassing the analyst consensus estimate of $30.29 million by 10%. However, this represents a 77.11% decrease in sales compared to $145.54 million in the same period last year.

Portfolio Pulse from Benzinga Newsdesk

November 28, 2023 | 11:33 am

SHOP

Piper Sandler analyst Clarke Jeffries has downgraded Shopify (NYSE:SHOP) from Neutral to Underweight and reduced the price target from $58 to $56, indicating a bearish outlook on the company's stock.

Portfolio Pulse from Benzinga Newsdesk

November 28, 2023 | 11:33 am

SQ

Square and Afterpay reported a record-breaking Black Friday and Cyber Monday with 70 million transactions, marking a 14% increase from the previous year. In-person shopping rose by 15%, while online cart sizes were 3.9 times larger than in-person. Additionally, 9% more businesses adopted omnichannel strategies to attract both in-person and online buyers. This data compares the 2022 to 2023 Black Friday through Cyber Monday weekend.

Portfolio Pulse from Benzinga Newsdesk

November 28, 2023 | 11:27 am

UXIN

Uxin Ltd (NASDAQ:UXIN), a Chinese used car retailer, reported a 42.5% Y/Y decline in Q2 FY24 sales to $48.8 million and a 35.8% decrease in transaction volume. The adjusted loss per ADS was $(0.01). Despite the decline, the gross margin improved to 6.2% from 1.3% Y/Y. The company aims for EBITDA profitability at the superstore level by March 2024 and overall company profitability by September 2024. Q1 revenue also fell by 53.8% Y/Y to $39.9 million. Uxin anticipates Q3 revenue between RMB 410 million to RMB 430 million. The stock is down 61.2% YTD but traded 2.15% higher premarket.

Portfolio Pulse from Anusuya Lahiri

November 28, 2023 | 11:23 am

EZFL

Ezfill Holdings has filed a Form S-1 with the SEC for a firm commitment public offering of its common stock. The size of the offering has not been disclosed.

Portfolio Pulse from Charles Gross

November 28, 2023 | 11:18 am